Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
31.16
+0.11 (0.35%)
At close: Apr 28, 2026, 4:00 PM EDT
31.78
+0.62 (1.99%)
After-hours: Apr 28, 2026, 5:42 PM EDT
HRMY Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for HRMY stock have an average target of 44.11, with a low estimate of 28 and a high estimate of 61. The average target predicts an increase of 41.56% from the current stock price of 31.16.
Analyst Consensus: Buy
* Price targets were last updated on Feb 25, 2026.
Analyst Ratings
The average analyst rating for HRMY stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 4 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $46 → $36 | Hold | Maintains | $46 → $36 | +15.53% | Feb 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +76.51% | Feb 25, 2026 |
| B of A Securities | B of A Securities | Sell Maintains $32 → $28 | Sell | Maintains | $32 → $28 | -10.14% | Feb 25, 2026 |
| Needham | Needham | Strong Buy Maintains $46 → $44 | Strong Buy | Maintains | $46 → $44 | +41.21% | Feb 25, 2026 |
| UBS | UBS | Strong Buy → Hold Downgrades $43 → $46 | Strong Buy → Hold | Downgrades | $43 → $46 | +47.63% | Feb 11, 2026 |
Financial Forecast
Revenue This Year
1.04B
from 868.45M
Increased by 19.75%
Revenue Next Year
1.17B
from 1.04B
Increased by 12.88%
EPS This Year
3.67
from 2.71
Increased by 35.46%
EPS Next Year
4.39
from 3.67
Increased by 19.66%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1B | 1.3B | ||||||
| Avg | 1.0B | 1.2B | ||||||
| Low | 964.0M | 918.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 26.9% | 27.9% | ||||||
| Avg | 19.8% | 12.9% | ||||||
| Low | 11.0% | -11.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.62 | 6.66 | |||
| Avg | 3.67 | 4.39 | |||
| Low | 2.47 | 3.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 70.5% | 81.3% | |||
| Avg | 35.5% | 19.7% | |||
| Low | -8.9% | -17.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.